Host-targeting agents in the treatment of hepatitis C: A beginning and an end?-Reference-Cited by-同舟云学术

Host-targeting agents in the treatment of hepatitis C: A beginning and an end?

Published:2013-11 Issue:2 Volume:100 Page:555-561
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Baugh James M.,Garcia-Rivera Jose A.,Gallay Philippe A.

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference81 articles.

1. New cyclophilin inhibitors unrelated to cyclosporine potently inhibit HCV replication and revert HCV-induced mitochondrial dysfunction;Ahmed-Belkacem;Hepatology,2012

2. Alisporivir (Alv) plus peg-interferon/ribavirin (Pr) in Hcv G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with Pr;Alberti;Journal of Hepatology,2012

3. The functions of animal microRNAs;Ambros;Nature,2004

4. Cyclophilin involvement in the replication of hepatitis C virus and other viruses;Baugh;Biological Chemistry,2012

5. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication;Berger;Proceedings of the National Academy of Sciences of the United States of America,2009

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophilin inhibition as a strategy for the treatment of human disease;Frontiers in Pharmacology;2024-07-08

2. Therapeutic strategies and promising vaccine for hepatitis C virus infection;Immunity, Inflammation and Disease;2023-08

3. Entry Inhibitors of Hepatitis C Virus;Advances in Experimental Medicine and Biology;2022

4. To Explore the Potential Targets and Current Structure-based Design Strategies Utilizing Co-crystallized Ligand to Combat HCV;Current Drug Targets;2021-04-08

5. Cyclophilin A: a key player for etiological agent infection;Applied Microbiology and Biotechnology;2021-01-25